To include your compound in the COVID-19 Resource Center, submit it here.

Celgene gets refusal to file letter for ozanimod

Celgene Corp. (NASDAQ:CELG) said FDA issued a refusal to file letter for an NDA for multiple sclerosis therapy ozanimod, which could be a

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE